Identification of genes that regulate the development, self-renewal and differentiation of stem cells is of vital importance for understanding normal organogenesis and cancer; such knowledge also underpins regenerative medicine. Here we demonstrate that chemical mutagenesis of mice combined with advances in hematopoietic stem cell reagents and genome resources can efficiently recover recessive mutations and identify genes essential for generation and proliferation of definitive hematopoietic stem cells and/or their progeny. We employed high-throughput FACS to analyze nine subsets of blood stem cells, progenitor cells, circulating red cells and platelets in >1,300 mouse embryos at embryonic day (E) 14.5. From 45 pedigrees we recovered six strains with defects in definitive hematopoiesis. We demonstrate rapid identification of a novel mutation in the c-Myb transcription factor that results in thrombocythemia and myelofibrosis as proof-of-principal of the utility of our FACSbased screen. Such phenotype-driven approaches will provide new knowledge of genes, protein interactions and regulatory networks which underpin stem cell biology.
ABSTRACT
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INTRODUCTION
Derived from the Greek word for blood (αιμα, haima), hematopoiesis describes the generation of fully differentiated effector blood cells from multi-potential, selfrenewing hematopoietic stem cells (HSCs). 1 There are two waves of hematopoiesis in vertebrates ( Figure 1A ). The primitive wave is derived from hemangioblasts that form in the posterior primitive streak and migrate onto the yolk sac (YS) from E7.0 2, 3 where they give rise to primitive erythroid progenitors (EryP) in association with endothelial and vascular smooth muscle cells. EryP proliferate and differentiate synchronously to generate large nucleated red cells which enter the circulation as the heart begins to beat at ~E9.0. 3, 4 Platelets are also generated in the YS and enter the fetal circulation early, where they may or may not perform a classical hemostatic function. 5 The definitive hematopoietic wave expands in the fetal liver (FL) from ~E11.5, but HSCs are produced before this time in the ventral wall of the dorsal aorta and YS. Their potential to make at least 8 different mature blood cell lineages is not realised until the FL bud is formed from the gut tube and a suitable microenvironment is established for HSC seeding. From E11.5-E15.5 there is a massive expansion of the FL which is initially geared for production of definitive enucleated red blood cells to sustain rapid fetal growth ( Figure 1A ). From ~E15.5, myeloid lineages are produced and hepatocytes begin to differentiate within the FL as it transforms from a hematopoietic organ into an adult liver.
We know much about the genes which are critical for definitive stem cell generation and differentiation from reverse genetic approaches in mice, primarily gene knockouts. 6 Most of the essential transcription factors were initially discovered as oncogenes, as proteins which bind to important cis-regulatory elements in other For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From genes, or by sequence homology. 1, 7 Some factors play dual roles in primitive and definitive hematopoiesis while others are relatively definitive-specific. c-Myb is an example of the latter, 8 whereas SCL/tal-1 and GATA2 play essential roles in both waves. 9, 10 Forward genetic screens using the mutagen ethylnitrosourea (ENU) offer a number of advantages over reverse genetics for gene discovery. 11 Most importantly, they are phenotype-driven and so make no presumptions about which genes are involved in a particular process. Resulting point mutations also mimic those which characterise the majority of human inherited and acquired genetic diseases, and point mutations can lead to hypo-or anti-morphic alleles in addition to loss-of-function alleles. The ability of mis-sense mutations to radically affect proteome regulatory networks and subsequent phenotypes has been well demonstrated in both yeast 12 and bacteria. 13 Mammalian examples are also beginning to be described from ENU mouse screens [14] [15] [16] including at the stem cell level. 17 Gain-of-function (dominant mutations) and precise mutations in critical cis-regulatory elements are also possible outcomes from ENU screens. These are difficult to achieve using reverse engineering technologies without leaving small marks (such as LoxP sites) behind.
A number of important genes for HSC and blood cell production have been discovered through ENU in zebrafish. 18 Initial screens focused on embryonic anemia so were biased towards finding mutations in patterning or primitive hematopoiesis.
While some mutations were found in known hematopoietic genes, 19 many more were in unexpected genes. 20, 21 Our screen builds upon numerous successful dominant or haplo-insufficient hematopoietic 22,23 and immunological 11, 14 screens to identify ENU phenodeviants in mice. We describe two complementary FACS-based assays to detect perturbations in subsets of definitive HSC/progenitors, red cells and platelets in For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From mid gestation (E14.5) mouse embyros. We conducted our screens on fetal tissues 24, 25 (liver and blood) rather than adult bone marrow to (a) minimise loss of lethal recessive phenotypes prior to birth, (b) access a hematopoietic organ (FL) containing quantifiable subsets of HSC/progenitors, (c) reduce time to screening of the animal, and (d) reduce project costs. To date, we have screened over 1300 G3 embryos from 45 pedigrees for 9 hematopoietic parameters in parallel and identified 6 recessive mutations. We have given these pedigrees Australian Aboriginal names to reflect the Australian origin of the screen, and as acknowledgment that our Aboriginal peoples understand land sustainability just as stem cells maintain and repair adult tissues after damage or degeneration.
MATERIALS AND METHODS

Mice
All eight wild-type strains -C57BL/6J (B6), C57BL/10SnJ (B10), C57L/J, BALB/b, C3H/HeH, CBA/CaJ, FVB/NJ and 129/SvEv -and ENU pedigrees (B6) were maintained at the Australian Phenomics Facility. The morning of vaginal plug observation was E0.5. ENU pedigree founder G0 B6 male mice were treated weekly with 90mg/kg ENU over 3 weeks. All mouse experiments were approved by the institutional review board of Australian National University.
Flow Cytometry
Full list of antibodies is listed in Supplementary Material. All cells were analyzed on an LSRII (Becton Dickinson, Mountain View, CA) and FACS data analyzed using FlowJo (Tree Star, Inc., Ashland, OR).
Hematological Analyses
Whole blood (175μl) from adult mice was collected into EDTA tubes and run through an Advia 120/2120 Hematology System analyzer (Siemens AG, Munich, Germany) loaded with mouse-specific software. Cytospins were at 500rpm for 4 mins in a Cytospin 3 (Shandon, Waltham, MA). Cells were fixed in 100% methanol and stained in May-Grünwald-Giemsa. Paraffin sections of spleen were stained with Hematoxylin & Eosin, Perl stain or reticulin using standard protocols (see Supplementary Methods).
Genomic Mapping and Genotyping
DNA from (B6×B10) F2 embryos was analyzed using a panel of 80 B6/B10 single nucleotide polymorphisms (SNPs) that on average span the mouse genome at 20Mb intervals. Full details of SNP marker design and genotyping is listed in Supplementary Material.
Gene Sequencing
Sequencing of candidate genes was to locate the causal ENU B6 nucleotide substitution. DNA was prepared from an individual affected mouse and primers designed for candidate genes to amplify all exons +/-15bp to cover splice junctions.
Primers are available upon request. Amplicons were then sequenced by the Sanger method on a 3730xl capillary sequencer (Applied Biosystems, Inc., Foster City, CA).
This automated platform used Big Dye Terminator chemistry v3.1 (Applied Biosystems). The raw trace files were analyzed using Lasergene software (DNASTAR, Inc., Madison, WI) against B6 reference genome. Mutations were confirmed in a second affected individual. 
Biochemistry
The E308G mutation on c-Myb that included an N-terminal HA tag was recreated using a PCR-based mutagenesis approach, following which the mutant was cloned into BamHI and XhoI sites of pcDNA3.1 (InVitrogen, Carlsbad, CA). Reporter and glutathione S-Transferase (GST) pull-down assays to detect interaction between Myb and CBP KIX were performed as described in Supplementary Material.
Statistics
Data were analyzed for significance between groups using a two-tailed Student's t test. Differences were considered significant at p < 0.05.
RESULTS
A Screen for Hematopoietic Stem/Progenitor Cells and Blood Production
Our primary aim was to find recessive mutations causing abnormal definitive HSC production or turnover. A secondary aim was mutations which resulted in defective red cell and/or platelet production. Most of the knowledge about HSC frequencies and behaviour has come from various assays using adult bone marrow. However, FL is a very rich source of HSCs that out-compete bone marrow stem cells in most scenarios. 26, 27 To efficiently screen for LT-HSC and progenitor cell phenotypes in FL, we first set up a high-throughput FACS assay using wild-type C57BL/6J (B6) mice ( Figure 1B ). We chose this strain for mutagenesis because we have extensive experience in using it for ENU screens, 11,14 the mouse reference genome was built using B6 DNA making ENU-generated SNP detection easier, and many monoclonal antibodies have often been utilised specifically in B6. In particular, functional HSC For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From assays such as competitive repopulation assays are easier using B6 congenic strains because of the availability of CD45 strain-specific antibodies.
Using an 8-colour single-stain protocol, 6 functionally distinct hematopoietic stem and progenitor cell subsets -long-term hematopoietic stem cells (LT-HSC), multi-potent progenitors (MPP), common lymphoid progenitors (CLP), common myeloid progenitors (CMP), granulocyte/macrophage progenitors (GMP), and megakaryocyte/erythrocyte progenitors (MEP) -were quantified in parallel ( Figure   1B ). Self-renewing LT-HSC were gated according to the 5-colour cKit+Lin-Sca1+CD150+flk2-cell surface phenotype, while MPP were cKit+Lin-Sca1+CD150-flk2+. 26, 27 The four subsets of lymphoid and myeloid progenitors were gated according to published protocols. 28, 29 By a separate 3-colour FACS analysis and cell size measurement on a log scale, we also established a companion high-throughput screening assay for subsets of blood cells and platelets in FB based on recently published work ( Figure 1C) . 3, 5 YSderived primitive red blood cells (RBC) were identified based on their large size, nucleus (i.e. Hoecsht (H)33342-positivitiy), and expression of the cell surface marker TER119. FL-derived definitive RBC were medium-sized and expressed TER119 but were enucleated (H33342-negative). Finally, platelets were very small in size and stained for CD41 but not H33342. Together, these 9 subsets of cells assayed in parallel provided a high-resolution snapshot of early hematopoiesis in both a primary tissue and the periphery ( Figure 1A ). The use of two complementary screening assays each with multiple phenotypic readouts also provided internal controls to minimize the identification of false positives.
Ontogeny of Hematopoietic Stem and Progenitor Cell Compartments
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We analyzed FL and FB samples from B6 embryos aged E12.5, E13.5 and E14.5 to examine the dynamics of stem and progenitor cell proliferation. A five-fold increase in nucleated cells in the FL was observed with each developmental day (Figure 2A ).
Primitive RBC formed the majority (~80%) of the circulating FB at E12.5, a frequency which dropped by ~20% with each developmental day ( Figures 1A and   2B ). This is consistent with the gradual switch from primitive to definitive erythroid cells in the circulation. 3, 4 We found primitive erythroid cells underwent progressive enucleation in the circulation to greater levels than realised until recently, 3 such that by E14.5 about 20% were enucleated ( Figure 1C ). The reduction in primitive RBC was mirrored by a relative increase in definitive RBC from ~5% at E12.5 to ~25% at E13.5 and ~50% at E14.5 ( Figure 2B ). By comparison, mean platelets counts of ~0.5-1% relative to red cells were relatively constant across developmental days ( Figure   2B ), consistent with substantial platelet production from the YS as well as the FL. 5 Frequencies ( Figure 2C ) and absolute numbers ( Figure 2D Based on these data, the optimal developmental age to conduct our screen was E14.5, when the primitive and definitive RBC compartments in FB were at ~50% relative frequencies (Figures 1 and 2 ) facilitating accurate quantification of both.
Also, mice harbouring targeted deletions of genes essential for definitive hematopoiesis survive to ~E14.5 because the primitive wave can sustain embryos til then. 8, 30 Furthermore, we reasoned loss-of-function or hypomorphic alleles of genes involved in both primitive and definitive hematopoieis such as Epo, EpoR or SCL/tal-1 might be viable or recently dead at E14.5. 31 Lastly, E14.5 FL is large and easy to process, whereas older FL is harder to dissociate into single cells.
Hematopoietic Stem Cell Compartments in Inbred Mouse Strains
Since an outcross to a non-B6 inbred strain is required to map the causative ENU mutation underlying any phenotype of interest, we needed to ensure the FACS assays were robust and identical in the mapping strain eventually chosen. Numerous phenotyping surveys encompassing a broad range of biological disciplines have been conducted in inbred strains 32, 33 Nevertheless, our choice of mapping strain to detect HSC phenodeviants was limited to B6-related and FVB/N strains. In addition, CLP frequency was similar to C57BL/6 levels in B6 variants and 129/SvEv mice but all other strains had lower frequencies ( Figure 3A ). Also, a shift in CD34 and FcγR cell surface staining resulted in ambiguous GMP frequencies for all but C57BL/10SnJ, while the CMP/MEP subsets were less variable across the strains tested ( Figure 3A and Supplementary Figure 1B ). Based on these observations, we outcrossed our ENU mutagenized B6 pedigrees to the C57BL/10SnJ (B10) strain since it showed the least variability in hematopoietic profile relative to B6 across all parameters examined, an unsurprising finding given their common ancestry 37 and close position on the mouse phylogenetic tree. 38 Although this meant a reduction in polymorphisms between these two strains and mapping power, 39 we felt this was superseded by the need to reliably identify phenodeviants on outcrossing.
Summary of ENU Pedigrees Screened
We chose a concentration of ENU based on many years of experience in the Australian Phenomics Facility. Previous experiments have determined that we generate approximately 30 mutations in coding genes in each founder G1 male using a standard 3 x 90mg/kg of ENU. 40 Using our FACS assays, we screened 1375 G3 embryos at E14.5 from 45 B6 ENU pedigrees and identified six strains with phenotypes in HSC/progenitors and/or early blood cell production. Supplementary Table 1 documents the first 1107 embryos and 34 pedigrees screened. Average litter size was 8 and the embryo resorption rate was ~15%. Some pedigrees showed a consistently higher rate of embryo resorption possibly indicative of either a dominant or recessive early embryonic lethal phenotype. We found six ENU pedigrees with reproducible defects defined as present in at least 3 independent litters. ENU11.21
(kandarra), ENU11.28 (booreana), and ENU11.211 (mulkirri) have been outcrossed and heritability confirmed. A further three pedigrees, ENU11.208 (chokerre), ENU11.235 (wonggan), and ENU11.312 (kamu), are in the process of outcrossing for mapping ( Table 1) .
Identification of the Booreana Mutant Phenotype
The ENU strain booreana (from the Aboriginal word for white) was so named because embryo #8 from the first litter of pedigree ENU11.28 ( Figure 4A ) showed an expansion of LT-HSCs ( Figure 4B and 4D) . Booreana homozygous embryos (boo/boo) are indistinguishable from littermates by inspection ( Figure 5A ). However, boo/boo FL has an increased frequency of LT-HSC (4-fold), MPP (3-fold), CLP (3-fold), variable CMP numbers, but decreased GMP (3-fold) and MEP (2-fold) ( Figure   4B ). That some cell subsets had expanded and others reduced strongly suggested a bona fide phenodeviant. The distinctive boo phenotype recurred in one embryo (#17) in the third litter of pedigree ENU11.28 ( Supplementary Figure 3) . In this case CMP numbers were normal but the other subsets were like those in the founder embryo. 
Booreana Embryos Harbor a Mutation in the Transactivation Domain of c-Myb
We generated a boo/boo DNA pool (n = 12) alongside an unaffected pool of To test the biochemical function of c-Myb E308G/E308G , we cloned the mutant cDNA into an expression vector and tested its ability to transactivate the myeloperoxidase gene promoter in reporter assays. In comparison to wild-type cMyb, the E308G mutation is completely inert ( Figure 5G ). There was slight residual function in the M303V TA domain mutation suggesting the E308G mutation is more severe. Since c-Myb has been reported to bind p300 and CBP via its TA domain, 23 we also asked whether the mutation in the acidic residue disrupted interaction. We found complete absence of binding of CBP to E308G and L302A mutations in GST pull-down assays in 293T cells ( Figure 5I ). Megakaryocytes in boo/boo mutants were also increased ~8-fold in the bone marrow and ~20-fold in the spleen as determined by CD41 staining (Figure 7) . In addition to an increase in number, there was an increase in nuclear ploidy of boo/boo megakaryocytes as determined by DRAQ5 incorporation in CD41+ cells (Figure 7) . 
Adult c-Myb
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DISCUSSION
Forward genetics offers the potential to find novel genes involved in any biological process if a robust assay is established for reliable detection of phenodeviants.
Dominant and recessive screens using high-throughput blood cell counting assays have successfully identified mutations in many hematopoietic genes. 11,14,22-25 Some were well known from previous studies while others were unexpected players. 24, 25 To our knowledge this is the first attempt to use quantitative FACS assays to detect perturbations in all the major definitive hematopoietic stem/progenitor cell subsets. Such an undertaking would be difficult in adult mice but our father-daughter mating strategy and fetal screen of G3s has enhanced the feasibility of such an undertaking; with a small team we have performed a pilot screen of 45 pedigrees and found 6 recessive mutations. The rapid cloning of a novel point mutation in the c-Myb oncogene provides proof-of-principal that informative mutations in key definitive stem cell genes can be identified by employing FACS and a recessive breeding strategy.
Embryonic recessive screens have simply relied on identification of visible
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From phenodeviants.
Strain Differences in HSC and RBC Antigen Expression
In the process of searching for an appropriate mapping strain we uncovered differences in surface expression of stem cell markers. For example, Sca1 is not expressed on the cell surface of HSCs in a number of commonly employed mouse strains such as BALB/c, C3H and CBA, and is weak in 129/Sv. This has implications for using Sca1 for the study of HSC biology in mice generated from gene targeted ES cell lines from a 129/Sv genetic background. One possibly trivial explanation is that the epitope recognised by the Sca1 monoclonal antibody (D7) is slightly divergent in the non-B6 strains due to a SNP that results in a conservative amino acid change.
Thus, Sca1 might be present in a variant form on HSCs in these strains. Further studies with different hybridomas or polyclonal anti-sera to Sca1 would be necessary to resolve this.
The TER119 red blood cell epitope does not seem to be present on embryonic red cells of some strains (C3H and FVB). TER119 is associated with glycophorin A but the precise epitope has not been identified. 41 Its absence in the primitive erythroid For personal use only. on November 16, 2017. by guest www.bloodjournal.org From wave of certain strains is intriguing; it is present in the definitive wave of these strains so the genes coding for TER119 must be present in the genomes, and the SNP argument is not likely to be valid in this case. Our results suggest failure of TER119 detection in certain strains is either due to a lack of a key regulatory protein in the primitive wave of these strains or of a partner protein or processing pathway component which normally leads to stable protein accumulation at cell surface. These results suggest TER119 has limited utility for the study of primitive erythroid cell differentiation in certain mouse strains.
c-Myb and Hematopoiesis
c-Myb is a well-known critical regulator of hematopoiesis and stem cell biology in other organ systems. 42 Gene knockout causes embryonic lethality by E15.5 from anemia. 8 Several ENU c-Myb alleles have been discovered using screens to detect blood abnormalities. The M303V mutation impairs interaction with transcriptional coactivators such as p300 and CBP. 23 
A Bottleneck on the Pathway to Gene Identification
We were able to identify the c-Myb mutation in booreana quickly because the boo/boo phenotype was distinctive and previous mutations and gene targeting of cMyb had been reported. 8, 23 However, identification of the causative mutation in our other pedigrees is taking longer for a number of reasons. First, there are limited SNPs between B6 and B10 so there is limited power to find meiotic recombinants in the intervals of interest. We have employed newly-described SNPs derived from deep sequencing of the B10 genome (Bruce Beutler, personal communication) to limit the interval in mulkirri to 34 Mb on chromosome 7 and the interval in kandarra to 26 Mb on chromosome 2 (Table 1) . However, these large intervals include 558 and 641
coding genes in the intervals of mulkirri and kandarra, respectively. Further meiotic recombinants will not help narrow the interval since the bottleneck is in SNPs, not recombination events. This is a consequence of using the B10 strain, but this is unavoidable due the strain-specificity of our assays. We have re-sequenced the coding exons of a few genes in these intervals which have a history in the hematopoietic field and are yet to find the causative mutation in either strain. It is possible the causative mutations reside outside coding regions (eg. promoters or enhancers) but this has been described rarely and is not the experience of our colleagues. 40 We believe it is more likely the genes of interest are novel with respect to hematopoiesis.
There has been a remarkably rapid advance in fast and cheap deep sequencing technologies which will aid mutation identification. These technologies are being used in large scale cancer re-sequencing projects but are also ideally suited to detecting ENU mutations. One advantage of using B6 mice for mutagenesis is the reference genome was generated using this strain, so unknown and confounding mouse strain specific SNPs are less likely to be troublesome, and the ENU-induced mutation is more likely to be obvious. There are different approaches in using these technologies which are much cheaper than deep sequencing of the whole mutant genome. We are currently using solution capture and re-sequencing of coding exons within the mulkirri and kandarra intervals as an efficient and relatively cost-effective way to find the causative mutations. 47 
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